FluoGuide A/S reaffirmed its 2026 financial outlook and confirmed overall progress remains on track. The company adjusted interim milestones for its lead product, FG001.
Part two of the FG001 clinical trial for head and neck cancer will now begin in the fourth quarter of 2026. Topline results for this trial are expected in the first half of 2027. This timeline represents a delay from the previous estimate of the second half of 2026.
FluoGuide maintains its schedule to enroll the first patient in the US Phase 2 study for aggressive brain cancer in July 2026.